Penalized Fair Regression for Multiple Groups in Chronic Kidney Disease
Organizations: Department of Health Policy, Stanford University, 615 Crothers Way Encina Commons MC6019 Stanford, CA 94305, USA · Psyfy Inc. · Department of Epidemiology and Population Health, Stanford University · Department of Health Policy, Stanford University
Abstract
Fair regression methods have the potential to mitigate societal bias concerns in health care, but there has been little work on penalized fair regression when multiple groups experience such bias. We propose a general regression framework that addresses this gap with unfairness penalties for multiple groups. Our approach is demonstrated for binary outcomes with true positive rate disparity penalties. It can be efficiently implemented through reduction to a cost-sensitive classification problem. We additionally introduce novel score functions for automatically selecting penalty weights. Our penalized fair regression methods are empirically studied in simulations, where they achieve a fairness-accuracy frontier beyond that of existing comparison methods. Finally, we apply these methods to a national multi-site primary care study of chronic kidney disease to develop a fair classifier for end-stage renal disease. There we find substantial improvements in fairness for multiple race and ethnicity groups who experience societal bias in the health care system without any appreciable loss in overall fit.
Figures & tables
| n | Prevalence | Sensitivity | Specificity | Accuracy | |
| Black | |||||
| Hispanic non-white | |||||
| Asian | |||||
| White | |||||
| Total |
| Unfairness | ||||||
| Method | Accuracy | Sensitivity | Mean | Black | Asian | HNW |
| Baseline | ||||||
| Max | ||||||
| Max | ||||||
| Group | ||||||
| Group A | Group B | Group C | |
| Setting 1 | 32 (0.15) | 20 (0.14) | 37 (0.16) |
| Setting 2 | 1 (0.03) | 20 (0.11) | 37 (0.13) |
| Setting 3 | 2 (0.04) | 2 (0.04) | 3 (0.05) |
| Diagnosis | Search Method | Query |
|---|---|---|
| ESRD | Text Query | “End stage renal disease” or “End stage renal failure” |
| eGFR | Preexisting | See repository |
| HbA1c | OMOP Concepts: Measurement | 4184637, 36304734 |
| Bilirubin | OMOP Concepts: Measurement | 4118986, 3024148, 4216632, 3024128 |
| Diastolic BP | OMOP Concepts: Measurement | 4298393, 3012888 |
| Systolic BP | OMOP Concepts: Measurement | 4152194, 3004249 |
| Missing | Overall | No ESRD | ESRD | |
| n | 0 | 67901 | 65084 | 2817 |
| Measurements | ||||
| Minimum eGFR, mean (SD) | 37179 | 48.3 (18.7) | 49.5 (17.9) | 22.3 (16.0) |
| Mean Diastolic BP, mean (SD) | 0 | 75.3 (7.9) | 75.4 (7.9) | 74.2 (8.8) |
| Mean Systolic BP, mean (SD) | 0 | 136.6 (11.9) | 136.5 (11.7) | 140.0 (14.1) |
| Mean HbA1c, mean (SD) | 44687 | 6.8 (1.4) | 6.8 (1.4) | 6.9 (1.6) |
Group Fairness
Group fairness measures and reduces disparities in how algorithms predict, rank, allocate resources, and make decisions for different groups.
See all 140 papers